Capricor Therapeutics, Inc.

Equities

CAPR

US14070B3096

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
5.3 ^USD	-2.21%		-3.11%	+8.38%

May. 09	Capricor Therapeutics, Inc. to Present Exosome Platform Updates At the American Society of Gene and Cell Therapy 27Th Annual Meeting	CI
Apr. 29	Transcript : Capricor Therapeutics, Inc. - Special Call

Capricor Therapeutics Appoints Leland J. Gershell as Chief Financial Officer

February 23, 2016 at 09:00 am EST

Capricor Therapeutics, Inc. announced the appointment of Leland J. Gershell, M.D., Ph.D. as Chief Financial Officer. Dr. Gershell brings to Capricor over 15 years of experience in the biotech sector, both within the industry and in finance as an equity research analyst and healthcare investor. He will report to Dr. Linda Marban, Capricor's Chief Executive Officer.

His appointment is effective immediately. Dr. Gershell comes to Capricor from Tonix Pharmaceuticals where he served as its Chief Financial Officer since early 2012.

Latest news about Capricor Therapeutics, Inc.

Capricor Therapeutics, Inc. to Present Exosome Platform Updates At the American Society of Gene and Cell Therapy 27Th Annual Meeting	May. 09	CI
Transcript : Capricor Therapeutics, Inc. - Special Call	Apr. 29
Capricor Therapeutics Gets Another Type-B Meeting With FDA for Duchenne Muscular Dystrophy Investigational Drug	Apr. 24	MT
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy	Apr. 24	CI
Capricor Therapeutics, Inc. to Present Positive 24-Month Results from its HOPE-2 Open-Label Extension Study at 2024 Muscular Dystrophy Association Clinical & Scientific Conference	Mar. 06	CI
Transcript : Capricor Therapeutics, Inc., Q4 2023 Earnings Call, Feb 29, 2024	Feb. 29
Earnings Flash (CAPR) CAPRICOR THERAPEUTICS Posts Q4 Revenue $12.1M, vs. Street Est of $10.6M	Feb. 29	MT
Capricor Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29	CI
Capricor Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Sector Update: Health Care Stocks Ease Late Afternoon	Feb. 27	MT
Sector Update: Health Care Stocks Decline Tuesday Afternoon	Feb. 27	MT
Capricor Secures Meeting With FDA on CAP-1002 Manufacturing Plans; Shares Rise	Feb. 27	MT
Capricor Therapeutics Announces Manufacturing Scale-Up of Cap-1002 Production At New San Diego Facility as It Continues Plans Toward Commercialization	Feb. 20	CI
Capricor Therapeutics Shares Rise 7% After Collaboration for Covid-19 Vaccine	Jan. 24	DJ
Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2	Jan. 24	CI
Capricor Therapeutics Announces Continuation of Phase 3 Hope-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis	Dec. 11	CI
Transcript : Capricor Therapeutics, Inc., Q3 2023 Earnings Call, Nov 14, 2023	Nov. 14
Earnings Flash (CAPR) CAPRICOR THERAPEUTICS Reports Q3 Revenue $6.2M, vs. Street Est of $3.17M	Nov. 14	MT
Capricor Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Transcript : Capricor Therapeutics, Inc., Parent Project Muscular Dystrophy - Special Call	23-10-25
HC Wainwright Raises Price Target on Capricor Therapeutics to $40 From $18, Keeps Buy Rating	23-10-04	MT
Sector Update: Health Care Stocks Lower Late Afternoon	23-09-29	MT
Sector Update: Health Care	23-09-29	MT
Top Midday Decliners	23-09-29	MT
Wall Street Set to Open Higher; Personal Consumption Inflation Data Lower Than Expected	23-09-29	MT

Chart Capricor Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. The Company leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins and small molecule therapeutics to potentially treat and prevent a diverse array of diseases.

Sector

Biotechnology & Medical Research

Calendar

2024-05-13 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Capricor Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.3 USD

Average target price

21 USD

Spread / Average Target

+296.23%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CAPRICOR THERAPEUTICS, INC.	+8.38%	167M
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs